CKD
MCID: CHR089
MIFTS: 73

Chronic Kidney Failure (CKD)

Categories: Blood diseases, Bone diseases, Genetic diseases, Nephrological diseases

Aliases & Classifications for Chronic Kidney Failure

MalaCards integrated aliases for Chronic Kidney Failure:

Name: Chronic Kidney Failure 39 12
Chronic Kidney Disease 12 30 6 44 15 17 3 64
Kidney Failure, Chronic 45 74
Chronic Renal Disease 12 15
Ckd 12 3
Chronic Renal Failure Syndrome 12
Chronic Kidney Disease Stage 5 74
Renal Failure - Chronic 12
Chronic Kidney Diseases 74
Chronic Renal Failure 77
Renal Failure Chronic 56
Crf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:784
ICD9CM 36 585.6
MeSH 45 D007676
NCIt 51 C9438
SNOMED-CT 69 46177005 90688005
ICD10 34 N18 N18.5 N18.9

Summaries for Chronic Kidney Failure

MedlinePlus : 44 You have two kidneys, each about the size of your fist. Their main job is to filter your blood. They remove wastes and extra water, which become urine. They also keep the body's chemicals balanced, help control blood pressure, and make hormones. Chronic kidney disease (CKD) means that your kidneys are damaged and can't filter blood as they should. This damage can cause wastes to build up in your body. It can also cause other problems that can harm your health. Diabetes and high blood pressure are the most common causes of CKD. The kidney damage occurs slowly over many years. Many people don't have any symptoms until their kidney disease is very advanced. Blood and urine tests are the only way to know if you have kidney disease. Treatments cannot cure kidney disease, but they may slow kidney disease. They include medicines to lower blood pressure, control blood sugar, and lower cholesterol. CKD may still get worse over time. Sometimes it can lead to kidney failure. If your kidneys fail, you will need dialysis or a kidney transplantation. You can take steps to keep your kidneys healthier longer: Choose foods with less salt (sodium) Control your blood pressure; your health care provider can tell you what your blood pressure should be Keep your blood sugar in the target range, if you have diabetes Limit the amount of alcohol you drink Choose foods that are healthy for your heart: fruits, vegetables, whole grains, and low-fat dairy foods Lose weight if you are overweight Be physically active Don't smoke NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Chronic Kidney Failure, also known as chronic kidney disease, is related to end stage renal failure and calciphylaxis, and has symptoms including cloudy (hemodialysis) (peritoneal) dialysis effluent An important gene associated with Chronic Kidney Failure is COL4A5 (Collagen Type IV Alpha 5 Chain), and among its related pathways/superpathways are Adipogenesis and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. The drugs Capsaicin and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are cardiovascular system and homeostasis/metabolism

PubMed Health : 64 About chronic kidney disease: Our kidneys are vital organs that clean our blood and affect many different bodily functions. Various medical conditions can cause the kidneys to stop working properly for a short time – for example, if blood isn’t pumped around the body properly or if an enlarged prostate or kidney stones make urine build up in the kidneys.But if the kidneys still aren’t working at full capacity more than three months later or are permanently damaged, then the problem is considered to be chronic kidney disease. The most common causes in adults are diabetes and high blood pressure.Older people are especially prone to developing chronic kidney disease. It often goes unnoticed for a long time because poorly functioning kidneys don’t cause any problems at first.Treatment mostly aims to stop the kidney disease from getting worse, or at least delay the process. It is also important to treat complications such as anemia, acidosis or changes in bone metabolism. If the kidneys fail completely, dialysis or a kidney transplant can prolong the person’s life.

Wikipedia : 77 Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney... more...

Related Diseases for Chronic Kidney Failure

Diseases in the Kidney Disease family:

Acute Kidney Failure Chronic Kidney Failure
Renal Infectious Disease Ren-Related Kidney Disease

Diseases related to Chronic Kidney Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 825)
# Related Disease Score Top Affiliating Genes
1 end stage renal failure 33.5 ACE AGT ALB COL4A5 CRP EPO
2 calciphylaxis 32.8 ALB EPO FGF23 PTH VDR
3 hypoparathyroidism 32.1 FGF23 GATA3 PTH
4 hyperphosphatemia 31.6 FGF23 PTH VDR
5 lipid metabolism disorder 31.6 ACE CRP INS LEP
6 arteries, anomalies of 31.5 ACE AGT ALB CRP INS LEP
7 diabetes mellitus, noninsulin-dependent 31.5 ACE AGT ALB CRP INS LEP
8 bone disease 31.5 B2M FGF23 PTH VDR
9 liver disease 31.4 ALB INS LEP PKD1 PKD2
10 myocardial infarction 31.4 ACE AGT ALB CRP INS REN
11 sleep apnea 31.4 ACE CRP INS LEP REN
12 osteomalacia 31.3 FGF23 PTH VDR
13 vascular disease 31.3 ACE ALB CRP INS REN
14 polycystic kidney disease 31.3 ACE PKD1 PKD2 REN
15 nephrolithiasis 31.3 FGF23 INS PTH VDR
16 microvascular complications of diabetes 3 31.2 ACE AGT ALB INS
17 iron deficiency anemia 31.2 CRP EPO FGF23
18 obstructive nephropathy 31.1 ACE AGT ALB REN
19 autosomal dominant polycystic kidney disease 31.1 ACE AGT ALB FGF23 PKD1 PKD2
20 atherosclerosis susceptibility 31.1 CRP INS TUG1
21 iga glomerulonephritis 31.1 ACE ALB REN
22 microvascular complications of diabetes 5 31.0 ACE ALB INS
23 liver cirrhosis 31.0 ALB LEP REN TTR
24 analbuminemia 31.0 ALB CRP EPO TTR
25 pre-eclampsia 30.9 AGT LEP REN TUG1
26 renal dysplasia 30.9 ACE AGT GATA3 REN
27 uremia 30.8 ALB B2M CRP EPO INS LEP
28 peripheral vascular disease 30.8 ACE ALB CRP
29 peripheral nervous system disease 30.8 ALB INS TTR
30 hypertension, essential 30.7 ACE AGT ALB COL4A5 INS LEP
31 coronary stenosis 30.7 ACE ALB CRP
32 carotid artery disease 30.7 ACE CRP REN
33 apnea, obstructive sleep 30.7 CRP INS LEP REN
34 rickets 30.6 FGF23 PTH VDR
35 primary hyperparathyroidism 30.6 ALB FGF23 PTH VDR
36 membranous nephropathy 30.6 ACE ALB B2M
37 morbid obesity 30.6 CRP INS LEP
38 hypercholesterolemia, familial 30.5 ACE AGT CRP INS
39 acute kidney failure 30.5 ALB B2M REN
40 glucose intolerance 30.5 CRP INS LEP
41 hypertensive encephalopathy 30.5 ACE EPO REN
42 uremic neuropathy 30.5 B2M EPO PTH
43 urinary tract obstruction 30.5 ALB B2M REN
44 pyelonephritis 30.5 ACE ALB CRP
45 hyperparathyroidism 30.5 EPO FGF23 PTH VDR
46 diabetic neuropathy 30.5 ACE EPO INS LEP
47 renal osteodystrophy 30.5 FGF23 PTH VDR
48 hypoaldosteronism 30.5 ACE REN
49 protein-energy malnutrition 30.5 ALB LEP TTR
50 multicystic dysplastic kidney 30.5 PKD1 PKD2 REN

Comorbidity relations with Chronic Kidney Failure via Phenotypic Disease Network (PDN): (show top 50) (show all 114)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Pancreatitis
Acute Proliferative Glomerulonephritis Acute Vascular Insufficiency of Intestine
Alcoholic Liver Cirrhosis Amyloidosis
Aortic Valve Disease 1 Bacteremia 2
Benign Essential Hypertension Benign Hypertensive Renal Disease
Benign Renovascular Hypertension Bladder Cancer
Bladder Neck Obstruction Bleeding Disorder, Platelet-Type, 11
Bronchitis Bronchopneumonia
Candidiasis Cardiac Arrest
Cardiogenic Shock Cerebral Atherosclerosis
Cerebrovascular Disease Chronic Intestinal Vascular Insufficiency
Chronic Myocardial Ischemia Chronic Rapidly Progressive Glomerulonephritis
Cystitis Decubitus Ulcer
Deficiency Anemia Dermatomycosis
Diabetic Polyneuropathy Disseminated Intravascular Coagulation
Duodenitis Encephalopathy
Esophageal Candidiasis Esophageal Disease
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Goodpasture Syndrome Gout
Heart Disease Hemolytic-Uremic Syndrome
Hepatic Encephalopathy Hepatorenal Syndrome
Hydronephrosis Hyperparathyroidism

Graphical network of the top 20 diseases related to Chronic Kidney Failure:



Diseases related to Chronic Kidney Failure

Symptoms & Phenotypes for Chronic Kidney Failure

UMLS symptoms related to Chronic Kidney Failure:


cloudy (hemodialysis) (peritoneal) dialysis effluent

MGI Mouse Phenotypes related to Chronic Kidney Failure:

47 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.49 ACE AGT B2M COL4A5 CRP EPO
2 homeostasis/metabolism MP:0005376 10.43 ACE AGT ALB B2M COL4A5 CRP
3 immune system MP:0005387 10.36 ACE AGT B2M COL4A5 CRP EPO
4 endocrine/exocrine gland MP:0005379 10.34 ACE ALB B2M FGF23 GATA3 INS
5 hematopoietic system MP:0005397 10.34 ACE B2M COL4A5 EPO FGF23 GATA3
6 cellular MP:0005384 10.33 ALB B2M EPO GATA3 INS LEP
7 growth/size/body region MP:0005378 10.32 ACE AGT B2M FGF23 GATA3 INS
8 digestive/alimentary MP:0005381 10.28 ALB B2M FGF23 GATA3 INS LEP
9 mortality/aging MP:0010768 10.22 ACE AGT ALB B2M COL4A5 EPO
10 adipose tissue MP:0005375 10.11 ACE AGT COL4A5 GATA3 INS LEP
11 integument MP:0010771 10.09 B2M EPO FGF23 GATA3 INS LEP
12 liver/biliary system MP:0005370 10.07 ACE AGT ALB B2M EPO INS
13 renal/urinary system MP:0005367 10.03 ACE AGT ALB COL4A5 FGF23 GATA3
14 limbs/digits/tail MP:0005371 9.95 EPO FGF23 LEP MKS1 PKD1 PTH
15 muscle MP:0005369 9.91 AGT ALB EPO GATA3 INS LEP
16 reproductive system MP:0005389 9.73 ACE AGT B2M FGF23 GATA3 INS
17 skeleton MP:0005390 9.28 EPO FGF23 GATA3 INS LEP MKS1

Drugs & Therapeutics for Chronic Kidney Failure

PubMedHealth treatment related to Chronic Kidney Failure: 64

The most suitable treatment for chronic kidney disease will depend on the cause and stage of the disease, as well as on the person’s life circumstances and preferences.If the kidneys are still working at a nearly normal level, treatment should aim to stop or slow down the progression of the disease. This is mainly done using medication to lower blood pressure levels and prevent cardiovascular disease. If you have diabetes, it's important to regulate your blood sugar levels.If complications such as anemia or bone metabolism disorders have already occurred, then more medications are used – such as medicines that contain iron or stimulate the production of blood, as well as medications called “phosphate binders.” If there is too much acid in your body, bicarbonates are used. In addition to the medication, the treatment will include a diet suited to the stage of the disease, drinking the right amounts of liquids and physical exercise.Dialysis or a kidney transplant are considered if the kidneys fail completely.In the vast majority of people with complete kidney failure, at least one of these options is possible. Some people make a conscious decision not to use either, accepting the fact that they could die soon afterwards. Palliative treatment may then be suitable for them – enabling a final phase of life that is as pleasant as possible.

Drugs for Chronic Kidney Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1029)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capsaicin Approved Phase 4 404-86-4 1548943
2
Simvastatin Approved Phase 4,Phase 3,Not Applicable 79902-63-9 54454
3
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
4
Peginterferon alfa-2b Approved Phase 4,Phase 1,Not Applicable 99210-65-8, 215647-85-1
5
Nitric Oxide Approved Phase 4,Phase 1,Phase 2,Not Applicable 10102-43-9 145068
6
Digoxin Approved Phase 4 20830-75-5 30322 2724385
7
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 616-91-1 12035
8
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
9
Ticagrelor Approved Phase 4,Phase 3,Phase 1,Phase 2 274693-27-5 9871419
10
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
11
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114798-26-4 3961
12
Olmesartan Approved, Investigational Phase 4,Phase 3,Not Applicable 144689-24-7, 144689-63-4 130881 158781
13
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145040-37-5 2540
14
Telmisartan Approved, Investigational Phase 4,Phase 3,Not Applicable 144701-48-4 65999
15
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 6493-05-6 4740
16
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137862-53-4 60846
17
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2 138402-11-6 3749
18
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
19
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
20
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
21
Nadroparin Approved, Investigational Phase 4
22
Dalteparin Approved Phase 4,Phase 2,Phase 3,Not Applicable 9005-49-6
23
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
24
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
25
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 54-31-9 3440
26
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
27
Spironolactone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 52-01-7, 1952-01-7 5833
28
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 2713 9552079
29
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
31
alemtuzumab Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 216503-57-0
32
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
33
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492 6473866
34
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
35
Bupivacaine Approved, Investigational Phase 4,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
36
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
37
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
38
Alendronate Approved Phase 4,Not Applicable 66376-36-1, 121268-17-5 2088
39
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
40
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
41
Pioglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 111025-46-8 4829
42
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
43
Fosinopril Approved Phase 4,Phase 3,Not Applicable 98048-97-6 55891
44
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
45
Denosumab Approved Phase 4,Phase 3,Phase 1 615258-40-7
46
Parathyroid hormone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9002-64-6
47
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7439-89-6, 15438-31-0 23925 27284
48
Phylloquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84-80-0
49
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
50
carbamide peroxide Approved Phase 4,Phase 3,Phase 2,Not Applicable 124-43-6

Interventional clinical trials:

(show top 50) (show all 3865)
# Name Status NCT ID Phase Drugs
1 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
2 Simvastatin Effect on End Stage Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin
3 Inspiratory Muscle Training in Patients With End Stage Renal Failure Unknown status NCT01347775 Phase 4
4 Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
5 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
6 Far Infrared Therapy on AV Fistula Flow, Endothelial Function and Echocardiography in ESRD Patients Unknown status NCT01138254 Phase 4
7 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
8 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
9 Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
10 NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED Unknown status NCT00501475 Phase 4 NAC Bicarbonate
11 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
12 Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery Unknown status NCT02447796 Phase 4 Propofol;Dexmedetomidine
13 Effect of Laparoscopic Sleeve Gastrectomy in the Morbidly Obese, Kidney Transplant Candidate Unknown status NCT01913392 Phase 4
14 Effects of On-Line Hemodiafiltration(HDF) on Vascular Health in Chronic Hemodialysis Patients Unknown status NCT00532597 Phase 4
15 A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Unknown status NCT02661295 Phase 4 Ferric Citrate
16 LMWH Infusion as Anticoagulation for Home HD Unknown status NCT02957877 Phase 4 Nadroparin;Unfractionated heparin
17 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
18 The Use of Furosemide in Patients on Dialysis Unknown status NCT01815892 Phase 4 Withdrawal of furosemide;furosemide administration
19 Body Composition Monitor in Hemodialysis Patients Unknown status NCT01103167 Phase 4
20 Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis Unknown status NCT00155363 Phase 4
21 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
22 Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis Unknown status NCT02452437 Phase 4 Oxycodone
23 Hypervolemia in ESRD Patients in Zonguldak (Prospective Study) Unknown status NCT01468363 Phase 4
24 Cardiovascular Protective Effect of Spironolactone in Hemodialysis Unknown status NCT00277693 Phase 4 Spironolactone (drug)
25 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
26 Intravenous Paricalcitol in Chronic Hemodialysis Patients Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
27 Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection Unknown status NCT02547103 Phase 4
28 Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients Unknown status NCT01111422 Phase 4 N-acetylcysteine
29 Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation Unknown status NCT00807144 Phase 4 Tacrolimus (Kidney transplant maintenance immunosuppression);Kidney transplant maintenance immunosuppression
30 RAAS Inhibitor Drugs in Dialysis Patients Unknown status NCT01635387 Phase 4 aliskiren
31 More Frequent Dialysis (>3 Treatments Per Week) Unknown status NCT00575497 Phase 4
32 2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula Unknown status NCT00993746 Phase 4 Bupivacaine plus lidocaine;Bupivacaine 30 ml
33 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
34 The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
35 Far Infrared Therapy on Peripheral Artery Disease in Hemodialysis Patients Unknown status NCT01095549 Phase 4
36 Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus Unknown status NCT01073501 Phase 4 Pregabalin;Placebo
37 Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients Unknown status NCT01570556 Phase 4
38 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Unknown status NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
39 Alendronate for Vascular Calcification in Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
40 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
41 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
42 Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
43 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
44 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
45 Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
46 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
47 Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
48 Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy Unknown status NCT01023373 Phase 4 Medical treatment
49 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
50 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)

Search NIH Clinical Center for Chronic Kidney Failure

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Kidney Failure cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: kidney failure, chronic

Genetic Tests for Chronic Kidney Failure

Genetic tests related to Chronic Kidney Failure:

# Genetic test Affiliating Genes
1 Chronic Kidney Disease 30

Anatomical Context for Chronic Kidney Failure

MalaCards organs/tissues related to Chronic Kidney Failure:

42
Kidney, Bone, Heart, Endothelial, Liver, Testes, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Chronic Kidney Failure:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Kidney Proximal Tubule Proximal Tubule Cells Affected by disease, potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Chronic Kidney Failure

Articles related to Chronic Kidney Failure:

(show top 50) (show all 5648)
# Title Authors Year
1
Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β2-microglobulin-related amyloidosis and indoxyl sulfate-induced atherosclerosis-Oshima Award Address 2016. ( 29869756 )
2019
2
Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3 Deficiency in Vascular Smooth Muscle Cells Prevents Arteriovenous Fistula Failure Despite Chronic Kidney Disease. ( 30587058 )
2019
3
Latent Tuberculosis Infection and Non-Infectious Co-morbidities: Diabetes Mellitus type 2, Chronic Kidney Disease and Rheumatic Arthritis. ( 30802622 )
2019
4
Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease. ( 30777405 )
2019
5
Short-Term Outcomes in Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: How Important Is Ethnicity? ( 30717613 )
2019
6
Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. ( 30717616 )
2019
7
Case of psoriasis vulgaris with atrial fibrillation, heart failure and chronic kidney disease which were found accidentally through blood examination during apremilast treatment. ( 30663127 )
2019
8
Chronic kidney disease predicts atrial fibrillation in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. ( 30650039 )
2019
9
Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease. ( 30593489 )
2019
10
Frequency of bacteriuria in dogs with chronic kidney disease: A retrospective study of 201 cases. ( 30767319 )
2019
11
Senescent Cells in Early Vascular Ageing and Bone Disease of Chronic Kidney Disease-A Novel Target for Treatment. ( 30717151 )
2019
12
Clinical impact of advanced chronic kidney disease on outcomes and in-hospital complications of Takotsubo Syndrome (broken-heart-syndrome): Propensity-matched national study. ( 30293663 )
2019
13
Bullous pemphigoid associated with linagliptin treatment in diabetic patients with chronic kidney disease. ( 30630688 )
2019
14
The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: A comprehensive review. ( 30666627 )
2019
15
Clinical Significance of Increased Serum Neopterin in Chronic Kidney Failure as a Biomarker of Cell-mediated Immunity. ( 30820177 )
2019
16
Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats. ( 30728778 )
2019
17
Endovascular Therapy Using Diluted Contrast Medium for Critical Limb Ischemia in a Patient with Chronic Kidney Disease. ( 30464136 )
2019
18
Is there association between chronic kidney disease and dental caries? A case-controlled study. ( 30818314 )
2019
19
Improving the appropriateness of depression treatment in patients with advanced chronic kidney disease. ( 30671913 )
2019
20
Carotid intima-media thickness is an independent predictor of all-cause mortality and cardiovascular morbidity in patients with diabetes mellitus type 2 and chronic kidney disease. ( 30909780 )
2019
21
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. ( 30857464 )
2019
22
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. ( 30753708 )
2019
23
Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus. ( 30697257 )
2019
24
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. ( 30697905 )
2019
25
Influence of chronic kidney disease on coronary plaque components in coronary artery disease patients with both diabetes mellitus and hypertension. ( 30607540 )
2019
26
Simplified end stage renal failure risk prediction model for the low-risk general population with chronic kidney disease. ( 30794622 )
2019
27
The correlation between fatty liver disease and chronic kidney disease. ( 30876789 )
2019
28
Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities. ( 30827925 )
2019
29
Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. ( 30347513 )
2019
30
Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. ( 29390103 )
2019
31
Cardiovascular disease risk among children with focal segmental glomerulosclerosis: a report from the chronic kidney disease in children study. ( 30903375 )
2019
32
Frozen shoulder in chronic kidney disease. ( 30824920 )
2019
33
Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study. ( 30682034 )
2019
34
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis. ( 30871566 )
2019
35
Association between hepatitis B virus infection and chronic kidney disease: A cross-sectional study from 3 million population aged 20 to 49 years in rural China. ( 30702585 )
2019
36
Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam. ( 30711348 )
2019
37
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. ( 30506144 )
2019
38
Effects of parathyroidectomy on the biology of bone tissue in patients with chronic kidney disease and secondary hyperparathyroidism. ( 30738215 )
2019
39
Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease. ( 30203374 )
2019
40
Hyperphosphatemia: a novel risk factor for mortality in chronic kidney disease. ( 30906759 )
2019
41
Correction: Prevalence of and risk factors for chronic kidney disease of unknown aetiology in India: secondary data analysis of three population-based crosssectional studies. ( 30885907 )
2019
42
Differential network enrichment analysis reveals novel lipid pathways in chronic kidney disease. ( 30887029 )
2019
43
Chronic kidney disease and acute kidney injury in arthroplasty patients over 65 years of age. ( 30888058 )
2019
44
What is the place of sclerostin in chronic kidney disease, atherosclerosis, and ageing? ( 30888601 )
2019
45
Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis. ( 30888644 )
2019
46
Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting. ( 30889484 )
2019
47
Association of Circulating Tissue Inhibitor of Metalloproteinases-1 and Procollagen Type III Aminoterminal Peptide Levels With Incident Heart Failure and Chronic Kidney Disease. ( 30890055 )
2019
48
Periostin contributes to renal and cardiac dysfunction in rats with chronic kidney disease: reduction of PPARα. ( 30890453 )
2019
49
Chronic kidney disease, cardiovascular risk markers and total mortality in older men: cystatin C versus creatinine. ( 30890591 )
2019
50
Effect of L-carnitine and conjugated linoleic acid supplements on haemoglobin levels and haptoglobin genotype in chronic kidney disease. ( 30890825 )
2019